1. Delivering clinical research to make patients, and the NHS, better Head & Neck SSG Research – 2015/16 30/04/2015 David Hwang Consultant Oncologist Wendy Cook Research Delivery Manager

2. Head and Neck Tumour Group National Perspective Data from Portfolio ODP – Cut off 21/08/15

3. Head and Neck Tumour Group National Perspective Data from Portfolio ODP – Cut off 21/08/15 Network 2014/20152015/2016 Commercial Non- Commercial TotalRankCommercial Non- Commercial TotalRank East Midlands086 1105510 Eastern074 1204411 Greater Manchester32012046022 5 Kent, Surrey and Sussex0142 904411 North East and North Cumbria0131 100999 North Thames52092145116177 North West Coast1191192704411 North West London059 13021 6 South London322212533237392 South West Peninsula1575814000 Thames Valley and South Midlands024 1500014 Wessex62993051058 1 West Midlands0165 8110118 West of England0243 4025 4 Yorkshire and Humber0279 2033 3

5. Head and Neck Tumour Group Open Studies South West Peninsula Data from Portfolio ODP – Cut off 21/08/15 Study Name UKCRN IDStudy TypeStudy Design Open to New Sites? Total Recruitment ART DECO 9562 Non- Commercial InterventionalNo7 De-ESCALaTE HPV 11723 Non- Commercial InterventionalYes2 HOPON 4550 Non- Commercial InterventionalYes6 IoN 10876 Non- Commercial InterventionalYes13 NCRN206 - LUX-adjuvant Afatinib after chemoradiation in primary unresectable HNC 11522CommercialInterventionalNo1 SEND 2069 Non- Commercial InterventionalYes1

6. Head & Neck Tumour Group Open Studies East Midlands Data from Portfolio ODP – Cut off 21/08/15 Study Name UKCRN IDStudy TypeStudy Design Open to New Sites? Total Recruitment De-ESCALaTE HPV11723 Non- Commercial InterventionalYes7 IoN10876 Non- Commercial InterventionalYes12 NCRN206 - LUX-adjuvant Afatinib after chemoradiation in primary unresectable HNC11522CommercialInterventionalNo4 SEND2069 Non- Commercial InterventionalYes8

7. Head and Neck Tumour Group Open Studies Eastern Data from Portfolio ODP – Cut off 21/08/15 Study Name UKCRN IDStudy TypeStudy Design Open to New Sites? Total Recruitment ART DECO9562 Non- Commercial InterventionalNo10 IoN10876 Non- Commercial InterventionalYes16 NIMRAD (NIMorazole/placebo plus RADiotherapy in head and neck cancer)16203 Non- Commercial InterventionalNo1 SEND2069 Non- Commercial InterventionalYes2

8. Head and Neck Tumour Group Open Studies Greater Manchester Data from Portfolio ODP – Cut off 21/08/15 Study Name UKCRN IDStudy TypeStudy Design Open to New Sites? Total Recruitment Head and Neck Cancer: molecular, cellular and immunological mechanisms8130 Non- Commercial ObservationalNo28 HOPON4550 Non- Commercial InterventionalYes4 IoN10876 Non- Commercial InterventionalYes17 NCRN - 3173 CheckMate 141: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 141 16460CommercialInterventionalNo2 NCRN206 - LUX-adjuvant Afatinib after chemoradiation in primary unresectable HNC11522CommercialInterventionalNo1 NCRN583 BKM120 + paclitaxel vs. paclitaxel + placebo14907CommercialInterventionalNo1 NIMRAD (NIMorazole/placebo plus RADiotherapy in head and neck cancer)16203 Non- Commercial InterventionalNo17 SEND2069 Non- Commercial InterventionalYes21

9. Head and Neck Tumour Group Open Studies Kent, Surrey and Sussex Data from Portfolio ODP – Cut off 21/08/15 Study Name UKCRN IDStudy TypeStudy Design Open to New Sites? Total Recruitment ART DECO9562 Non- Commercial InterventionalNo12 De-ESCALaTE HPV11723 Non- Commercial InterventionalYes10 HOPON4550 Non- Commercial InterventionalYes1 IoN10876 Non- Commercial InterventionalYes18 SEND2069 Non- Commercial InterventionalYes64

10. Head and Neck Tumour Group Open Studies North East and North Cumbria Data from Portfolio ODP – Cut off 21/08/15 Study Name UKCRN IDStudy TypeStudy Design Open to New Sites? Total Recruitment ART DECO9562 Non- Commercial InterventionalNo9 De-ESCALaTE HPV11723 Non- Commercial InterventionalYes6 IoN10876 Non- Commercial InterventionalYes48 Resources for Living (R4L) Pilot16705 Non- Commercial BothNo17 SEND2069 Non- Commercial InterventionalYes7 THRIFT15036 Non- Commercial ObservationalNo2

11. Head and Neck Tumour Group Open Studies North Thames Data from Portfolio ODP – Cut off 21/08/15 Study Name UKCRN IDStudy TypeStudy Design Open to New Sites? Total Recruitment ART DECO9562 Non- Commercial InterventionalNo17 ElaTION17373 Non- Commercial BothYes (LC)6 Genetic factors involved in eyelid mBCC and SGC14687 Non- Commercial ObservationalYes (LC)54 IoN10876 Non- Commercial InterventionalYes12 NCRN362 - Safety of PC-A11 with laser light application in recurrent head & neck SCC11926CommercialInterventionalNo6 NCRN583 BKM120 + paclitaxel vs. paclitaxel + placebo14907CommercialInterventionalNo2 PATRIOT17568 Non- Commercial InterventionalNo6 SEND2069 Non- Commercial InterventionalYes130 SIP SMART: Swallowing Intervention package - Self Monitoring, Assessment & Rehabilitation Training 17043 Non- Commercial BothNo13

12. Head and Neck Tumour Group Open Studies North West Coast Data from Portfolio ODP – Cut off 21/08/15 Study Name UKCRN IDStudy TypeStudy Design Open to New Sites? Total Recruitment ART DECO9562 Non- Commercial InterventionalNo3 DAHANCA 2113565 Non- Commercial InterventionalYes3 De-ESCALaTE HPV11723 Non- Commercial InterventionalYes3 HOPON4550 Non- Commercial InterventionalYes67 NCRN - 3173 CheckMate 141: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 141 16460CommercialInterventionalNo1 NIMRAD (NIMorazole/placebo plus RADiotherapy in head and neck cancer)16203 Non- Commercial InterventionalNo3 SEND2069 Non- Commercial InterventionalYes15

13. Head and Neck Tumour Group Open Studies North West London Data from Portfolio ODP – Cut off 21/08/15 Study Name UKCRN IDStudy TypeStudy Design Open to New Sites? Total Recruitment ART DECO9562 Non- Commercial InterventionalNo2 ElaTION17373 Non- Commercial BothYes (LC)21 IoN10876 Non- Commercial InterventionalYes5

14. Head and Neck Tumour Group Open Studies South London Data from Portfolio ODP – Cut off 21/08/15 Study Name UKCRN IDStudy TypeStudy Design Open to New Sites? Total Recruitment ART DECO 9562Non-CommercialInterventionalNo40 BoHEMIaN Study 13125Non-CommercialInterventionalNo20 COAST - Cisplatin Ototoxicity attenuated by Aspirin Trial 13400Non-CommercialInterventionalNo32 De-ESCALaTE HPV 11723Non-CommercialInterventionalYes7 ElaTION 17373Non-CommercialBothYes (LC)5 Genetic factors involved in eyelid mBCC and SGC 14687Non-CommercialObservationalYes (LC)37 HOPON 4550Non-CommercialInterventionalYes1 INSIGHT 13860Non-CommercialInterventionalNo36 IoN 10876Non-CommercialInterventionalYes23 NCRN - 2376 Caprelsa in MTC 15014CommercialObservationalNo2 NCRN - 3173 CheckMate 141: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 141 16460CommercialInterventionalNo21 NCRN206 - LUX-adjuvant Afatinib after chemoradiation in primary unresectable HNC 11522CommercialInterventionalNo25 NCRN583 BKM120 + paclitaxel vs. paclitaxel + placebo 14907CommercialInterventionalNo1 NIMRAD (NIMorazole/placebo plus RADiotherapy in head and neck cancer) 16203Non-CommercialInterventionalNo3 PATRIOT 17568Non-CommercialInterventionalNo7 SEND 2069Non-CommercialInterventionalYes5 T4 immunotherapy of head and neck cancer 19183Non-CommercialInterventionalNo1

15. Head and Neck Tumour Group Open Studies Thames Valley and South Midlands Data from Portfolio ODP – Cut off 21/08/15 No open studies on Portfolio ODP

16. Head and Neck Tumour Group Open Studies Wessex Data from Portfolio ODP – Cut off 21/08/15 Study Name UKCRN IDStudy TypeStudy Design Open to New Sites? Total Recruitment ART DECO9562 Non- Commercial InterventionalNo10 COAST - Cisplatin Ototoxicity attenuated by Aspirin Trial13400 Non- Commercial InterventionalNo31 ElaTION17373 Non- Commercial BothYes (LC)6 Head and Neck Cancer: molecular, cellular and immunological mechanisms8130 Non- Commercial ObservationalNo700 HOPON4550 Non- Commercial InterventionalYes3 IoN10876 Non- Commercial InterventionalYes7 NCRN - 3173 CheckMate 141: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 141 16460CommercialInterventionalNo6 SEND2069 Non- Commercial InterventionalYes28

17. Head & Neck Tumour Group Open Studies West Midlands Data from Portfolio ODP – Cut off 21/08/15 Study Name UKCRN IDStudy TypeStudy Design Open to New Sites? Total Recruitment ART DECO9562 Non- Commercial InterventionalNo30 CANC - 3672 - Phase II MEDI4736 in SCCHN19009CommercialInterventionalNo1 COAST - Cisplatin Ototoxicity attenuated by Aspirin Trial13400 Non- Commercial InterventionalNo11 De-ESCALaTE HPV11723 Non- Commercial InterventionalYes39 HOPON4550 Non- Commercial InterventionalYes11 IoN10876 Non- Commercial InterventionalYes2 NIMRAD (NIMorazole/placebo plus RADiotherapy in head and neck cancer)16203 Non- Commercial InterventionalNo9 SEND2069 Non- Commercial InterventionalYes23

18. Head & Neck Tumour Group Open Studies West of England Data from Portfolio ODP – Cut off 21/08/15 Study Name UKCRN IDStudy TypeStudy Design Open to New Sites? Total Recruitment ART DECO9562 Non- Commercial InterventionalNo24 De-ESCALaTE HPV11723 Non- Commercial InterventionalYes34 Developing a core information set for consent to oral cancer surgery15348 Non- Commercial ObservationalYes (LC)117 HOPON4550 Non- Commercial InterventionalYes3 IoN10876 Non- Commercial InterventionalYes20 NIMRAD (NIMorazole/placebo plus RADiotherapy in head and neck cancer)16203 Non- Commercial InterventionalNo2

19. Head & Neck Tumour Group Open Studies Yorkshire and Humber Data from Portfolio ODP – Cut off 21/08/15 Study Name UKCRN IDStudy TypeStudy Design Open to New Sites? Total Recruitment ART DECO9562 Non- Commercial InterventionalNo48 COAST - Cisplatin Ototoxicity attenuated by Aspirin Trial13400 Non- Commercial InterventionalNo9 De-ESCALaTE HPV11723 Non- Commercial InterventionalYes70 HOPON4550 Non- Commercial InterventionalYes21 IoN10876 Non- Commercial InterventionalYes17 NCRN206 - LUX-adjuvant Afatinib after chemoradiation in primary unresectable HNC11522CommercialInterventionalNo6 NIMRAD (NIMorazole/placebo plus RADiotherapy in head and neck cancer)16203 Non- Commercial InterventionalNo4

20. Head & Neck Tumour Group South West Peninsula Sites Data from Portfolio ODP – Cut off 21/08/15

21. Head & Neck Tumour Group South West Peninsula Sites Data from Portfolio ODP – Cut off 21/08/15 Trust 2014/20152015/2016 Commercial Non- Commercial TotalCommercial Non- Commercial Total Northern Devon Healthcare NHS Trust044000 Plymouth Hospitals NHS Trust015 000 Royal Cornwall Hospitals NHS Trust000000 Royal Devon and Exeter NHS Foundation Trust11819000 South Devon Healthcare NHS Foundation Trust012 000 Taunton and Somerset NHS Foundation Trust088000 Yeovil District Hospital NHS Foundation Trust000000

22. Head & Neck Tumour Group South West Peninsula Open Studies 1 Data from CRN SWP Activity Data from EDGE July 2015 AcronymUKCRN IDStudy TypeTrust Investigator Name End DateTarget Total Recruitment 2015/2016 Recruitment RTT ART-DECO9562Non-Commercial Plymouth Hospitals NHS Trust Roy, Dr Amy31-Dec-2084019 ART-DECO9562Non-Commercial Royal Devon and Exeter NHS Foundation Trust Hwang, Dr David 26-Feb-161250-43 ART-DECO9562Non-Commercial Taunton and Somerset NHS Foundation Trust Jankowska, Dr Petra 29-Feb-16200-34 De-ESCALaTE HPV11723Non-Commercial Royal Devon and Exeter NHS Foundation Trust Hwang, Dr David 28-Feb-17520-9 HeadandNeck50009894Non-Commercial Northern Devon Healthcare NHS Trust Hwang, Dr David 31-Dec-14550-52 HeadandNeck50009894Non-Commercial Taunton and Somerset NHS Foundation Trust Jankowska, Dr Petra 31-Dec-1436310-37 HOPON4550Non-Commercial Northern Devon Healthcare NHS Trust Bowden, Dr John 28-Feb-18300-64 HOPON4550Non-Commercial Taunton and Somerset NHS Foundation Trust Blanco- Guzman, Manuel 28-Feb-18200-73 IoN10876Non-Commercial Royal Devon and Exeter NHS Foundation Trust Goodman, Dr Andrew 16-May-164130247 NCRN206 - LUX-adjuvant Afatinib after chemoradiation in primary unresectable HNC 11522Commercial Royal Devon and Exeter NHS Foundation Trust Hwang, Dr David 31-May-17510-41

23. Division 1 Duncan Wheatley, Clinical Specialty Lead duncan.wheatley@rcht.cornwall.nhs.uk 01872 258312duncan.wheatley@rcht.cornwall.nhs.uk Subspecialty lead David Hwang david.hwang@nhs.net 01392 406203david.hwang@nhs.net Wendy Cook, Research Delivery Manager wcook1@nhs.net 01392 406995 wcook1@nhs.net Ann Courtman, Administrator ann.courtman@nhs.net ann.courtman@nhs.net 01392 406966 23